Position in LGVN
as of Jun 30, 2026
· filed Jul 8, 2026
Position Value
$7,639
New position
Shares Held
10,867
first reported quarter
Ownership
0.034%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#24
of 39 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Valeo Financial Advisors, LLC holds $6,495,341 across 14 Biotechnology names. LGVN ranks #14 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
3,787 | $1,881,116 | |
| 2 | ARGX |
Argenx SE
|
1,077 | $999,208 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,289 | $803,743 | |
| 4 | RLAY |
Relay Therapeutics, Inc.
|
35,687 | $667,703 | |
| 5 | MRNA |
Moderna, Inc.
|
7,412 | $519,062 | |
| 6 | VCEL |
Vericel Corp
|
9,289 | $413,267 | |
| 7 | TGTX |
Tg Therapeutics, Inc.
|
6,033 | $331,453 | |
| 8 | TARS |
Tarsus Pharmaceuticals, Inc.
|
3,838 | $241,563 |
All Filings in LGVN
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $7,639 | 10,867 | Shares | Sole | 2026-07-08 | |
| No filing history on record for this holder in this stock. | ||||||